Third Point’s Ventyx Biosciences VTYX Stock Holding History

Third Point’s Portfolio VTYX Stock Details VTYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,000,000	Closed	-$32.8M	–	54
2022 Q4	$32.8M	Sell	1,000,000 -3,312,834	-77%	-$98.1M	0.55%	21
2022 Q3	$151M	Hold	4,312,834	–	–	2.72%	9
2022 Q2	$52.7M	Hold	4,312,834	–	–	1.25%	18
2022 Q1	$58.5M	Hold	4,312,834	–	–	0.76%	29
2021 Q4	$83.1M	Buy	+4,312,834	New	+$81.7M	0.58%	39

Other funds holding VTYX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Third Point's VTYX Position: Q1 2023 in Review

Third Point sold out of Ventyx Biosciences (VTYX) in Q1 2023, closing a stake of 1,000,000 shares — an estimated $32.8M sold.

Third Point first reported a position in VTYX in Q4 2021 and held it in 5 quarters. The position peaked at $151M in Q3 2022. 146 funds tracked by Wall St. Rank hold VTYX as of Q1 2023.

Third Point reported no remaining Ventyx Biosciences position as of Q1 2023 after selling out during the quarter.
Third Point sold 1,000,000 Ventyx Biosciences shares in Q1 2023, an estimated $32.8M.
Third Point first reported a position in Ventyx Biosciences in Q4 2021 and held it in 5 quarters.
Third Point's Ventyx Biosciences position peaked at $151M in Q3 2022.
146 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2023.

Based on Third Point's 13F filing for Q1 2023, filed 15 May 2023.